3-[4-(Imidazo[4,5-b]pyridin-3-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-sulfonamide | 575465-29-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3-[4-(Imidazo[4,5-b]pyridin-3-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-sulfonamide
• CAS: 575465-29-1
• 化学式: C₂₁H₂₂N₄O₂S₂
• 分子量: 426.563
• InChiKey: HUHGYRGOQLLHKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  氯甲酸丁酯 、 3-[4-(Imidazo[4,5-b]pyridin-3-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-sulfonamide 在 吡啶 、 2-(吡咯烷-1-基)吡啶 作用下， 以147.9 mg的产率得到butyl N-[3-[4-(imidazo[4,5-b]pyridin-3-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT₂ Receptor Agonist

  摘要：

  The first druglike selective angiotensin II AT(2) receptor agonist (21) with a K-i value of 0.4 nM for the AT(2) receptor and a K-i > 10 muM for the AT, receptor is reported. Compound 21, with a bioavailability of 20-30% after oral administration and a half-life estimated to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44(mapk), enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats. Thus, the peptidomimetic 21 exerts a similar biological response as the endogenous peptide angiotensin II after selective activation of the AT2 receptor. Compound 21, derived from the prototype nonselective AT(1)/AT(2) receptor agonist L-162,313 will serve as a valuable research tool, enabling studies of the function of the AT2 receptor in more detail.

  DOI：

  10.1021/jm049715t
• 作为产物：
  描述：

  3-<(4-Bromophenyl)methyl>-3H-imidazo<4,5-b>pyridine 在 sodium hydroxide 、 四(三苯基膦)钯 、 苯甲醚 、 三氟乙酸 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 3.0h， 生成 3-[4-(Imidazo[4,5-b]pyridin-3-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-sulfonamide
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT₂ Receptor Agonist

  摘要：

  The first druglike selective angiotensin II AT(2) receptor agonist (21) with a K-i value of 0.4 nM for the AT(2) receptor and a K-i > 10 muM for the AT, receptor is reported. Compound 21, with a bioavailability of 20-30% after oral administration and a half-life estimated to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44(mapk), enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats. Thus, the peptidomimetic 21 exerts a similar biological response as the endogenous peptide angiotensin II after selective activation of the AT2 receptor. Compound 21, derived from the prototype nonselective AT(1)/AT(2) receptor agonist L-162,313 will serve as a valuable research tool, enabling studies of the function of the AT2 receptor in more detail.

  DOI：

  10.1021/jm049715t

文献信息

• Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT₂ Receptor Agonist
  作者：Yiqian Wan、Charlotta Wallinder、Bianca Plouffe、Hélène Beaudry、A. K. Mahalingam、Xiongyu Wu、Berndt Johansson、Mathias Holm、Milad Botoros、Anders Karlén、Anders Pettersson、Fred Nyberg、Lars Fändriks、Nicole Gallo-Payet、Anders Hallberg、Mathias Alterman

  DOI：10.1021/jm049715t

  日期：2004.11.1

  The first druglike selective angiotensin II AT(2) receptor agonist (21) with a K-i value of 0.4 nM for the AT(2) receptor and a K-i > 10 muM for the AT, receptor is reported. Compound 21, with a bioavailability of 20-30% after oral administration and a half-life estimated to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44(mapk), enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats. Thus, the peptidomimetic 21 exerts a similar biological response as the endogenous peptide angiotensin II after selective activation of the AT2 receptor. Compound 21, derived from the prototype nonselective AT(1)/AT(2) receptor agonist L-162,313 will serve as a valuable research tool, enabling studies of the function of the AT2 receptor in more detail.